Solid Biosciences (SLDB) Change in Account Payables (2017 - 2026)

Solid Biosciences has disclosed Change in Account Payables across 10 years of filings, most recently posting $2.3 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $2.3 million, up 403.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $767000.0 (down 76.49% YoY), and the FY2025 annual result was -$1.1 million, down 149.57% from the prior year.
• Change in Account Payables came in at $2.3 million for Q1 2026 at Solid Biosciences, up from -$5.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q3 2025 to a low of -$5.9 million in Q4 2022.
• The 5-year median for Change in Account Payables is $287000.0 (2022), against an average of -$151588.2.
• Across the five-year window, Change in Account Payables tumbled 1136.14% in 2022 and soared 3766.2% in 2023, its largest moves.
• Solid Biosciences' Change in Account Payables stood at -$5.9 million in 2022, then surged by 102.27% to $134000.0 in 2023, then jumped by 508.21% to $815000.0 in 2024, then plunged by 745.03% to -$5.3 million in 2025, then jumped by 144.15% to $2.3 million in 2026.
• The last three Change in Account Payables figures came in at $2.3 million (Q1 2026), -$5.3 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.